Literature DB >> 34535454

Kidney Effects of Empagliflozin in People with Type 1 Diabetes.

David Z I Cherney1, Petter Bjornstad2, Bruce A Perkins3, Julio Rosenstock4, Dietmar Neubacher5, Jan Marquard6, Nima Soleymanlou6.   

Abstract

Entities:  

Keywords:  clinical trial; diabetes; diabetes mellitus; diabetic kidney disease; empagliflozin; glomerular filtration rate; glucosides; kidney function decline; kidney protection; sodium-glucose co-transporter-2 inhibitor; type 1

Mesh：

Substances：

Year:  2021        PMID： 34535454      PMCID： PMC8729416          DOI： 10.2215/CJN.07700621

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  5 in total

1.  Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat.

Authors:  Scott C Thomson; Timo Rieg; Cynthia Miracle; Hadi Mansoury; Jean Whaley; Volker Vallon; Prabhleen Singh
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-09-21       Impact factor: 3.619

2.  Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.

Authors:  David Z I Cherney; Bruce A Perkins; Nima Soleymanlou; Maria Maione; Vesta Lai; Alana Lee; Nora M Fagan; Hans J Woerle; Odd Erik Johansen; Uli C Broedl; Maximilian von Eynatten
Journal:  Circulation       Date:  2013-12-13       Impact factor: 29.690

3.  Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.

Authors:  Julio Rosenstock; Jan Marquard; Lori M Laffel; Dietmar Neubacher; Stefan Kaspers; David Z Cherney; Bernard Zinman; Jay S Skyler; Jyothis George; Nima Soleymanlou; Bruce A Perkins
Journal:  Diabetes Care       Date:  2018-10-04       Impact factor: 19.112

4.  Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial.

Authors:  Megumi Oshima; Brendon L Neuen; JingWei Li; Vlado Perkovic; David M Charytan; Dick de Zeeuw; Robert Edwards; Tom Greene; Adeera Levin; Kenneth W Mahaffey; Luca De Nicola; Carol Pollock; Norman Rosenthal; David C Wheeler; Meg J Jardine; Hiddo J L Heerspink
Journal:  J Am Soc Nephrol       Date:  2020-09-30       Impact factor: 10.121

5.  Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.

Authors:  Megumi Oshima; Meg J Jardine; Rajiv Agarwal; George Bakris; Christopher P Cannon; David M Charytan; Dick de Zeeuw; Robert Edwards; Tom Greene; Adeera Levin; Soo Kun Lim; Kenneth W Mahaffey; Bruce Neal; Carol Pollock; Norman Rosenthal; David C Wheeler; Hong Zhang; Bernard Zinman; Vlado Perkovic; Hiddo J L Heerspink
Journal:  Kidney Int       Date:  2020-12-11       Impact factor: 10.612
  5 in total
  1 in total

1.  Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis.

Authors:  Elisabeth B Stougaard; Peter L Kristensen; Urd Kielgast; Henrik U Andersen; Yasmin Hamid; Peter H Gæde; Esben Søndergaard; Gry H Dørflinger; Karen K Fjeldborg; Klavs W Hansen; Henrik H Thomsen; Thuraya M J Al-Imar; Michael Røder; Vikas S Sridhar; David Cherney; Peter Rossing; Frederik Persson
Journal:  Diab Vasc Dis Res       Date:  2022 Sep-Oct       Impact factor: 3.541
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.